Category Archives: Company

Scrip Pharmaceuticals profiles Forendo Pharma

Forendo Pharma CEO, Risto Lammintausta, was interviewed by Scrip Pharmaceuticals for an Emerging Company Profile section of the publication: “Forendo Pharma: Tackling The Endometriosis Challenge”. Get pdf version of the Scrip article by clicking here SCRIP is a leading source of news and strategic analysis for the global pharmaceutical industry, with over 14,000 registered users […]

Forendo Pharma nominates world class scientific advisory board and elects Professor Linda Giudice as the chairperson

Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, announces the nomination of its Scientific Advisory Board today. Forendo is developing tissue-specific hormone inhibitors to rebalance local estrogen metabolism in endometrial tissues. The key differentiator of the company’s lead HSD17B1 inhibitor compared to other drug treatments is the ability to act […]

Forendo awarded at the European Venture Summit

Forendo Pharma was one of the Top 25 Award Winners of the European Venture Contest in Dusseldorf, Germany. Forendo was presented by Maarit Merla, Head of Business Development. European Venture Summit Award Winners Over 100 investors and business angels chose the Top 25 emerging companies of the 2016 European Venture Contest at the continent’s biggest […]

Forendo in the Team Finland Health portal

Forendo Pharma is in the Team Finland Health portal of Finpro, Finland’s Trade and Investment Promotion Agency. represents the entire Finnish health care sector’s know-how through one digital portal and presents a comprehensive view and specific set of health care offerings from Finland. The website can be found at and it is constantly updated. […]

Meet us in Stockholm during Bio-Europe Spring

Forendo Pharma will participate in the BIO-Europe Spring® partnering conference in Stockholm, Sweden, during April 4th to 6th 2016. We will be meeting with potential licensing partners for our Fispemifene program. In order to schedule a meeting with us, please use the conference PartneringONE system or send us a message: We look forward to seeing […]

Forendo selected one of the most promising start-up companies in Finland

Forendo Pharma was selected as one of 20 most promising start-up companies in Finland, by Talouselämä, a highly respected finance magazine in Finland. Talouselämä is the only finance magazine published weekly in Finland and also the largest of its kind within the Nordic market. The selection of the most promising start-up companies was based on […]

Meet us in San Francisco during Biotech Showcase 2016

Forendo Pharma will be in San Francisco, California, for meetings with partners during Biotech Showcase and JP Morgan conference, from January 11th to 13th 2016. Biotech Showcase is the leading investor conference for mid-small cap and private biotech and life science companies. Our company presentation will be on Monday, January 11th, at 3:30 pm. Please contact […]

“Growth in Sight” prize awarded to Forendo Pharma

Entrepreneurial Spirit of Turku awards were shared in three categories in Creative Business Camp. Forendo was awarded by “Growth in Sight” prize.

Press Release: Successful closing of a new investment round.

Forendo Pharma closes EUR 12 million Series A financing round to develop a novel targeted therapy for endometriosis Turku, Finland, October 22nd, 2014. Forendo Pharma today announced the successful closing of a EUR 12 million new investment round. Novartis Venture Fund and MS Ventures will participate in the financing round, alongside the current major shareholders […]

Press Release: Fispemifene US development and commercialization rights licensed to Apricus Biosciences Inc.

Forendo Pharma announces the US licensing of fispemifene to Apricus Biosciences targeting urological conditions in men Turku, Finland, October 20th, 2014. Forendo Pharma Oy announced today that it has entered into a definitive agreement to out-license the US development and commercialization rights for fispemifene to Apricus Biosciences Inc. Fispemifene is a selective estrogen modulator (SERM), […]